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blinded to presence of MS. Associations were assessed by logistic regression. 
Results: The study included 3,528 subjects; 67% were male; age averaged 63+12 years; 
57.7% had significant (270% stenosis), 11 .l% mild/moderate, and 31 .O% no CAD (~10% 
stenosis). MS was present in 48% of patients; specifically, 39% had high FG; 52% high 
TG; 71% low HDL; 76% high S/DBP; and 58% high BMI. MS predicted increased risk of 
significant CAD (odds ratio [OR] of significant vs. no CAD= 1.40, 95% Cl 1.21-1.62, 
p<O.OOl). High FG (OR=l.91, Cl 1.63223, p<O.OOl) and low HDL (O&1.38. Cl 1.18- 
1.62, pcO.OOl), but not TG, BP, or BMI, were individually predictive of CAD. In multivari- 
able modeling, CAD was predicted by age, gender, high FG (OtXl.75, Cl 1.48-2.06), 
and low HDL (O&1.45, Cl 1.22-1.72)(all p<O.OOl). Similar results (with somewhat 
greater OR for FG, HDL) were found when restricting analysis to younger subjects 
(malesc55 years, females ~65 years). 
Conclusion: In a large, prospective observational study, the MS was predictive of CAD, 
and PV was carried by high FG and low HDL. FG and HDL deserve particular attention in 
risk factor assessment and prevention in subjects at risk for CAD. 
channel. KA~p channel is also located in pancreas 0 cells. K,,, channel in pancreas 8 
cells is closed by glucose and regulates insulin release. 
Purpose. This study was undertaken to assess the interaction between acute hypergly- 
cemia and ischemic preconditioning in patients with AMIMethods. We studied 549 
patients with a first anterior wall AMI who underwent coronary angiography within 12 
hours after the onset of AMI. Acute hyperglycemia was considered to be present if 
patients had plasma glucose21 1 .l mmolJL (200 mgldl) on hospital admission. Prodromal 
angina was defined as angina episode(s) occurring within 24 hours before the onset of 
AMI. Serial measurements of left ventricular ejection fraction (LVEF) were obtained in 
434 patients (79%) before reperfusion therapy and before discharge. 
Aesulb. In 377 patients without acute hyperglycemia, prodromal angina was associated 
with significantly larger Improvement of LVEF (10.1*13.6% vs 5.9+13.3%, p=O.O15) and 
lower 30.day mortality (0% (95% Cl O-3.0) vs 6.7% (4.2-10.5). p=O.OOl). However, in the 
presence of acute hyperglycemia (n=172), there was no significant difference in the 
change in LVEF (5.6+9.9% vs 5.4+13.3%, p=O.94) and 30.day mortality (8.1% (95% Cl 
3.5-17.5) vs 8.2% (4.4-14.8), pEO.98) between patients with prodromal angina and 
patients without. Multivariate analysts showed that prodromal anglna was an mdepen- 
dent predictor of predischarge LVEF in patients without acute hyperglycemia (p=O.O19) 
and not in patients with acute hyperglycemia (p=O.96). 
Conclusion Acute hyperglycemia abolished ischemic preconditionmg effect of prodro- 
mal angina. Our findings may provide a potentlal explanation for the adverse outcome of 
patients with AMI and acute hyperglycemia. 
3:15 p.m. 
1050-l 05 The Medicine, Angioplasty, or Surgery Study (MASS II 
Registry): A Comparison of Diabetic and Nondiabetic 
Patient’s Outcome in Medical Therapy, Coronary 
Angioplasty, and Bypass Surgery During the First Year 
Follow-Up 
Paula R. Soares, Whady Hueb, Bernard J. Gersh, Desiderio Favarato, Luiz M. Cesar. 
Protasio L. Luz. Seraio A. Oliveira. Jose F. Ramires, Heart Institute Medical School 
University of Sao P&lo. Sao Paula, Brazil, Mayo Clinic, Rochester, MN 
Diabetes is known to have a worse prognosis among patients with coronary artery dis- 
ease. In MASS II Registry we compared medical treatment (MT), surgety (CABG) and 
angioplasty (PCI) in patients with multivessel coronary disease. The present study com- 
pared the one-year outcome of the patients divided in two subgroups: diabetic (D) and 
non-diabetic (ND) patients in each of the therapeutic options. 1080 patients were treated 
with CABG (451), PCI (305) and MT (324). The primaly end point was considering as the 
composite events (CE) of cardiac-related deaths, myocardial infarction (Ml) and new 
revascularization (NR) in the first year of follow-up. The results are presented in the table 
1. 
Conclusion: In MASS II Registry during the first year follow-up study there were no statis- 
tical differences in the frequency of composite events between diabetic and non-diabetic 
patients in each of the three therapeutic groups. On the other hand, when outcomes 
were compared among patients undergoing PCI, CABG or MT, there was a statistically 
significant benefit for CABG on the therapy in diabetic patients.. 
Table I 
Group 
PCI 
N Death% Ml % NR % CE % 
D 75 5.3 2.7 8.0 16.0 
ND 230 2.6 6.5 10.9 20.0 
Total 305 3.3 5.6 10.2 19.0 
CABG D 154 3.9 0.6 0.0 4.5’ 
ND 297 2.7 1.0 0.3 4.0 
Total 451 3.1 0.9 0.2 4.2 
MT D 115 5.2 1.7 6.1 13.0 
ND 209 1.4 1.9 5.7 9.1 
Total 324 2.8 1.9 5.9 10.5 
*CABG “s MT “s PCI, p=O.O028 
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1068A-MP-204 Impact of Diabetes on Clinical, Echocardiographic, and 
Electrocardiographic Characteristics of Myocardial 
Infarction 
Costantlna Manes Marc A. Pfeffer. John D. Rutherford, Sally Greaves, Jean-Lucien 
Rouleau, Scott D. Solomon, BrIgham &Women’s Hospital, Boston, MA 
Background Diabetes mfluences the clinical presentation and course of acute myocar- 
dial infarction (AMI). We investigated the Impact of diabetes on clinical, echocardlo- 
graphic and electrocardiographic characteristics of 272 pts with Q-wave anterior AMI 
enrolled in the Healing and Early Afterload Reducing Therapy (HEART) Trial Methods: 
Patients underwent ECG testing within 24h (baseline) and at predischarge (median day 
7) after AMI, and echocardiography at baseline and at 14 days. From both ECGs we cal- 
culated the Selvester CIRS score, the sum of ST segment elevation and the number of 
neaative T waves in leads I, avL. VI-V6. Left ventricular eiection fraction ILVEF) and inf- 
arct segment length were assessed by echocardiography. Results: Diabetics (n=56, 
20.6%) were similar to non-diabetics (n=216. 79.4%) with resoect to initial and 14-dav 
Infarct size es evidenced by maximal CK, ejection fraction and infarct segment length 
(Table). However, diabetics demonstrated a higher Killip class, greater QRS score at 
baseline and predlscharge and fewer negative T waves on predischarge ECG, even after 
excluding patients with prior myocardial infarction (n=43, 16%). Conclusion: Diabetes 
may modify the clinical and electrocardiographic response to myocardial infarction inde- 
pendently of infarct size or ventricular function. 
Age, yr 
Killip Class >I, % 
Maximal CK, mU/mL 
Baseline LVEF. % 
Baseline Infarct Seyment Length, % 
Day 14 LVEF, % 
Day 14 Infarct Segment Length, % 
Baseline Sum ST Elevation, mm 
Diabetics Non-Diabetics P 
(n=56) (n=216) VSIUS 
60.8 * 10.9 59.6 * 13.1 0.5 
34% 19% 0.01 
2593 * 1887 2484 f 2012 0.71 
51.6 * 10.1 52.2 f. 9.4 0.67 
27.2 * 9.8 25.8 f 11 .O 0.36 
54.5 * 10.3 56.5 * 8.9 0.14 
20.6 * 12.2 17.9 * 13.0 0.16 
11.5 * 9.2 10.5 * 7.9 0.44 
Baseline Number Negative T waves 0.7 f 1.4 0.8 f 3.2 0.85 
1068A-MP Moderated Poster Baseline QRS Score 4.3 * 2.9 3.4 * 2.6 0.03 
Session...Hyperglycemia and Diabetes in Predischarge Sum ST Elevation, mm 4.5 f 3.0 4.6 f 3.3 0.9 
Acute Coronary Syndromes II Predischarge Number Negative T 1.4* 1.7 2.6 * 2 2 0.001 
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1068A-MP-203Acute Hyperglycemia Abolishes lschemic 
Preconditioning: A Possible Mechanism for Adverse 
Outcome of Patients With Acute Myocardial Infarction 
and Acute Hyperglycemia 
Masaharu Ishihara, lchiro Inoue, Takuji Kawagoe, Yuji Shimatani, Satoshi Kurisu, Kenji 
Nishioka. Takashi Umemura, Shuji Nakamura, Masashi Yoshida, Hiroshima City 
Hospital, Hiroshima, Japan 
Background. Acute hyperglycemia has been shown to be an independent predictor of 
adverse outcome after acute myocardial Infarction (AMI). Prodromal anglna occurring 
shortly before the onset of AMI has cardioprotective effect by the mechanism of ischemic 
precondltloning. lschemic preconditioning is promoted by opening of mitochondrial K,, 
Predlscharge QRS Score 5.2 * 3.1 4.0 r 2.5 0.01 
3:30 p.m. 
1068A-MP-205 Impact of Known and Newly Diagnosed Diabetes 
Mellitus After a Myocardial Infarction 
Davtd Aauilar, Scott D. Solomon, Lars Kober, Jean-Luclen Rouleau, Hicham Skali, John 
J. McMurray, Gary S. Francis, Marc Hems. Rafael Diaz, Yuri N. Belenkov, Sergei 
Varshavsky, Jeffrey D. Leimberger, Robert M. Califf. Marc A. Pfeffer, Brigham 8 
Women’s Hospital, Boston, MA 
Background Diabetes mellitus (DM) is associated with adverse outcomes in patients 
(pts) presenting with an acute myocardial infarction (AMI). but little IS known of the risk of 
newly diagnosed DM. 
Methods The VALsartan In Acute myocardial iNfarcTion (VALIANT) trial identified 
14,808 pts with an AMI complicated by either clinical or radiologic signs of heart failure 
and/or evidence of left ventricular (LV) systolic dysfunction. Assessment of diabetic sts- 
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tus occurred at the time of presentation with AMI and at randomization Into VALIANT 
(median 4.6 days after presentation). Pts with a history of DM or insulin use prior to the 
qualifying MI were defined as previously known DM (n=3.421). Newly diagnosed DM 
(n=565) was defined as pts with DM. some of whom required diabetic therapy at random- 
ization; none had known DM at presentation. The primary outcome was 30-day mortality. 
Results: Compared with known DM, pts with new DM were younger and had less hyper- 
tension, dyslipidemia. or prior cardiovascular disease, but had similar LV ejection fraction 
and Killip class at presentation. As anticipated, known DM had a higher 30-day mortality 
than that for non-diabetics. However, the overall adjusted risk for death associated with 
new DM was more similar In magnitude to previous DM than that for non-diabetics. 
Conclusion : Previously known DM is associated with higher do-day mortality in high-nsk 
pts presenting with an AMI. Despite less cardiac co-morbidity, newly diagnosed DM has 
a similar prognosis to previously known DM. 
Mean age 
LV ejection fraction (available for 77% 
of patients) 
Killip class > I 
Hypertension 
Dyslipidemia 
Prior MI 
Prior heart failure 
Prior stroke 
30.day mortality 
Adjusted hazard ratio for 30-day 
mortality (95% Cl) 
Known DM New DM 
(n=3,421) (n=565) 
NC+ 
diabetics 
(n=10,795 
66.6 * 10.4 63.9* 11.8’ 
34.4 * 10.4 34.1 * 10.4 
76.5% 75.6% 
70.3% 54.5%’ 
42.4% 21.7%’ 
34.7% 22.1%’ 
22.5% 9.7%’ 
9.4% 3.4%* 
5.0% 5.2% 
1.22 (1.01, 1.47) 1.24 (0.65, 
1.80) 
64.4 * 
12.2 
34.9 * 
10.2 
70.4% 
50.3% 
26.3% 
26.1% 
12.7% 
5.2% 
3.7% 
1 .oo 
(Referent 
e) 
*New DM vs Known DM, p <O.OOl 
3:45 p.m. 
1066A-MP-206 Prognostic Value of C-Reactive Protein in Diabetic 
Patients With Unstable Angina 
Javier N. Guena. Juan J. Fuselli. Carlos P. Boissonnet. Enrique Fairman. Alfred0 
Piombo, Juan Gagliardi, DIC Group, Buenos Aires, Argentina 
Background: In diabetic (DBT) patients (p), atherosclerotic plaques contain more inflam- 
matory cells, suggesting higher plaque vulnerability. 
Purpose: To determine the prognostic value of HS C-reactive protein (CRP) in DBT p 
with unstable angina (UA), in order to predict in-hospital death and/or MI (D/Ml). 
Methods: Multicenter, prospective study. Of the 317 consecutive p herein included, 67 
were diabetic (21 .l%). CRP (positive value: higher tertile) and cTnT (positive value: 3 0.1 
@ml) were measured at admission >= 6 hours from qualifying episode. In-hospital D/MI 
rate was 7.6%. CRP values were higher in DBT p than in non-DBT p: 1.64 * 2.5 vs 1.23 
f 2.9 mg/dl: p=O.OOl, t test (prior log transformation). D/MI was higher in DBT p (14.9% 
vs 5.6%. p=O.OZ) and in p with CRP (+) (11.3% vs 5.7%, p=O.O4). In a logistic regression 
model including CRP and cTnT. cTnT (c) was predictive of D/Ml (OR 3.5, Cl 95% 1.5- 
6.2, p=O.O05), whereas CRP was not (~~0.3). In the subgroup of DBT p, the Incidence of 
D/Ml was 29.2% in p with CRP (+) vs 7.0% in those with CRP (-) (OR 5.5, Cl 95% 1.3- 
23.6, p=O.O4) (Figure). In the logistic regression analysis performed in DBT p, CRP (+) 
was an independent predictor of D/MI (OR 4.6, Cl 95% 1.03-20.4. p=O.O46), whereas 
cTnT (+) was not. 
Conclusion: CRP levels are higher in DBT p with unstable angina. This marker is a stron- 
ger predictor of D/Ml than cTnT(+) I” this subgroup of p. These data suggest that plaque 
inflammation plays a major role in the genesis and evolution of plaque instability in DBT p 
with unstable angina. 
Non DBT DBT 
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1071-106 The Effect of Combination Use of Ticlopidine and 
Aspirin on 30-Day Mortality in Patients With Acute 
Myocardial Infarction 
Hlrova Mizunq Hiroshi Sate, Kunihiro Kinjo, Dalsaku Nakatani, lssei Shiotani, Eiji 
Hishida. Atsushi Hiravama. Kazuhisa Kodama. Masatsuou Hori. Osaka Acute Coronarv 
I  1  
Insufficiency Study (OACIS) group, Osaka University, Osaka, Japan 
Background. Combination therapy with clopidogrel and aspirin is proved to be superior 
to aspirin alone in the prevention of major vascular ischemic events in patients with acute 
coronary syndrome without ST-segment elevation in the CURE trial. However, advan- 
tage of the combination use of thienopyridines in broad spectrum of acute myocardlal inf- 
arction (AMI) has not been thoroughly clarified. We evaluated the effect of combination 
use of ticlopidine on thirty-day mortality in patients of AMI including ST-elevation infarc- 
tion. Subjects and methods. Of consecutive 2723 patients with AMI who registered to 
Osaka Acute Coronary Insufficiency Study, 1709 patients receiving ticlopidine and/or 
aspirin were enrolled in this study. Patients receiving other antiplatelets were excluded. 
The patients were divided into two groups according to the antiplatelet therapy: group 
treated by aspirin alone (n=768) and group treated by combination use of aspirin and 
ticlopidine (n=941). We compared thirty-day clinical outcome and major adverse event 
between the two groups by unadjusted Kaplan-Meier method, chi-square analysis and 
multivariate logistic regression models. Results. Within thirty days of onset, combination 
therapy group showed significantly lower all-cause mortality (0.9% versus 5.9%, 
p<O.OOOl) than aspirin group. After adjustment by patient characteristics, coronary risk 
factors and therapies, combination therapy remained as an independent predictor of 
thirty-day mortality (Odds ratio 0.16, [95% Cl 0.0046.0.511. p=O.O023). Combination ther- 
apy also decreased a risk of a composite of cardiovascular death and Ml (Odds ratio 
0.45, [95% Cl 0.24-0.641, p=O.O13). Significant diflerences were not observed in major 
bleeding between the two groups. Conclusion.Though it is not in a randomized fashion, 
our data suggested that combination use of ticlopidine has more favorable effect on 
thirty-day prognosis than aspirin monotherapy when applied to a broad spectrum of 
patients with AMI. 
1071-107 Predictors and Long-Term Mortality of Atrioventricular 
Block After Acute Myocardial Infarction Treated With 
Thrombolysis 
Trip J. Meine, Sana M. Al-Khatib, John H. Alexander, Christopher C. Granger, Rakhi 
Kilaru. Kathryn Williams, E. Magnus Ohman, Eric J. Topol, Robert M. Califf, Duke Clmical 
Research Institute, Durham. NC 
Background: Since the advent of thrombolylic therapy, several studies have suggested 
that the rate of post-myocardial Infarction atrwentricular block (AVB) remains high and 
is associated with increased mortality. We sought to further delineate the predictors of 
AVB and the long-term mortality of patients developing AVB in the setting of ST-segment 
elevation myocardial infarction treated with thrombolytic therapy. 
Methods: We combined four studies of ST-segment elevation myocardial infarction 
(GUSTO-I, GUSTO-lib, GUSTO-III and ASSENT-II) into a large database (n=75.993). 
We identified independent predictors of second and third degree AVB and compared the 
6.month and l-year mortality rates of patients with AVB (5,251) with those of patients 
without AVB (70,742). 
Results: The incidence of AVB was 6.9%. Significant Independent predictors of AVB are 
summarized in the table. Adjusted mortality was significantly higher in patients with AVB 
than patients without AVB at 6 months (OR 1.6, 95% Cl 1.4-l .6) and at 12 months (OR 
1.3, 95% Cl 1.1-1.5). 
Conclusion: In the thrombolytic era, AVB is not only a common complication of ST-seg- 
ment elevation myocardial infarction, but portends higher mortality. Future studies should 
focus on determining therapies that are effective at reducmg the mortality rates of these 
patients. 
